Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the…
16,940$
-0,94%
Echtzeit-Aktienkurs Zymeworks Inc.
Bid:
Ask:
Nachrichten zur Zymeworks Inc. Aktie
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
…
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the…
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
…
Zymeworks Inc. 2024 Q4 - Results - Earnings Call Presentation
…
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the…
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase By Investing.com
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase…
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
…
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms…
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
…
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
ZYMEWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymeworks Inc. on Behalf of Zymeworks Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
…
Zymeworks files to sell 5.09M shares for its holders
…
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…